US biotech major Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals (Nasdaq: IONS) have expanded their strategic collaboration through a new 10-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological diseases.
Ionis shares were up 14% at $52.26 in premarket trading following the announcement this morning.
This collaboration capitalizes on Biogen’s expertise in neuroscience research and drug development and Ionis’ leadership in RNA targeted therapies with the goal of developing a broad pipeline of investigational therapies. It builds upon a productive collaboration that produced Spinraza (nusinersen), the first and only approved treatment for patients with spinal muscular atrophy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze